NCT00295594View on ClinicalTrials.gov

Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation.

PHASE3CompletedINTERVENTIONAL
Enrollment

627

Participants

Timeline

Start Date

March 31, 2005

Primary Completion Date

June 30, 2007

Study Completion Date

June 30, 2007

Conditions
Liver Transplantation
Interventions
DRUG

tacrolimus

Immunosuppression

Trial Locations (41)

1082

Budapest

3000

Leuven

3010

Bern

8091

Zurich

9000

Ghent

14004

Córdoba

15006

A Coruña

15706

Santiago

18012

Granada

20122

Milan

20162

Milan

20251

Hamburg

24105

Kiel

24128

Bergamo

28007

Madrid

28034

Madrid

28035

Madrid

30120

Murcia

30625

Hanover

31008

Pamplona

33100

Udine

35128

Padua

41013

Seville

41345

Gothenburg

45122

Essen

46009

Valencia

53105

Bonn

55131

Mainz

70124

Bari

75105

Uppsala

80131

Napoli

90134

Palermo

91054

Erlangen

Unknown

Liège

Copenhagen

Leeds

Newcastle

00130

Helsinki

71-455

Szczecin

50-326

Wroclaw

08035

Barcelona

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00295594 - Comparing Efficacy & Safety of Tacrolimus With/Without MMF or Monoclonal Anti-IL2R Antibody in Liver Transplantation. | Biotech Hunter | Biotech Hunter